Genomic testing–guided treatment for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study uses your tumor’s genetic test results to help match you to the most suitable treatment when standard options have failed or don’t exist. It may help by targeting therapies based on specific gene changes found in your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have advanced or metastatic solid cancer that worsened after first-line treatment, or there is no standard treatment option
- You have a usable genetic test result (tumor tissue or blood), done by an approved lab, or you may provide tissue/blood for central testing
- You can sign consent and are expected to live at least 12 weeks
- You have recovered enough from your most recent cancer treatment, and you are not currently on anti-cancer treatment in the last 2 weeks
- You are not pregnant or breastfeeding (and won’t plan pregnancy during the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial builds a large database using your existing tumor genetic test results (DNA and/or RNA). It may help researchers better understand advanced cancers and use gene patterns to guide future care.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
This trial tests whether using a personalized approach (matching your tumor's genetic profile to a targeted drug) can help people with advanced solid cancers live longer. It is for people whose cancer is not responding to standard treatments and who have a genetic change that can be targeted by an FDA-approved drug not usually used for their cancer type.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.